Serous Borderline Tumor: Diagnosis, Treatment, and Prognosis

Serous borderline tumors of the ovary sit in a gray zone between clearly benign ovarian cysts and invasive ovarian cancer. They account for roughly 10 to 15 percent of all epithelial ovarian tumors, tend to strike at a younger age than ovarian carcinoma, and carry an overwhelmingly favorable prognosis when caught at an early stage. Yet the word “borderline” can leave patients and families uneasy, because the tumor is not entirely harmless: recurrences happen, peritoneal implants can complicate the picture, and in rare cases the disease transforms into something more aggressive. Understanding how these tumors are found, staged, and managed goes a long way toward putting the diagnosis in perspective.

What Sets a Serous Borderline Tumor Apart From Ovarian Cancer

The defining feature is that a serous borderline tumor proliferates more than a benign cyst but does not destructively invade the surrounding tissue the way a carcinoma does. Under the microscope, pathologists see fibrous stalks covered in crowded, multilayered epithelial cells that branch into complex papillary structures. Cells detach and shed from those papillae, and mild-to-moderate nuclear atypia is present, yet there is no frank stromal invasion.¹ When destructive invasion into the stroma does appear, the tumor is reclassified as a low-grade serous carcinoma.² That distinction matters enormously for treatment and prognosis.

How These Tumors Are Found

Imaging

Many serous borderline tumors are discovered incidentally during pelvic ultrasound for unrelated complaints, or they come to attention because of bloating, pelvic pain, or an enlarged ovary. MRI offers characteristic features that help radiologists narrow the diagnosis before surgery. On T2-weighted images, the tumors tend to show a papillary architecture with hyperintense tissue and hypointense internal branching. Contrast enhancement is typical.³ MRI can help distinguish these tumors from simple cysts or from high-grade ovarian cancer, though no imaging modality can make the diagnosis with certainty.⁴

Blood Tests

CA-125, the classic ovarian cancer blood marker, is often elevated in serous borderline tumors but is far from diagnostic on its own. Newer markers like HE4 and the ROMA algorithm, which combine HE4 and CA-125, have not shown meaningful improvement over CA-125 alone for borderline tumors. A study from the TOC Consortium found no significant difference in HE4 expression between borderline tumors and benign disease, and CA-125 by itself was actually better at distinguishing borderline tumors with invasive implants from benign conditions than either HE4 or ROMA.⁵ In practice, blood markers help raise suspicion but do not replace tissue examination.

Frozen Section During Surgery

Because the definitive diagnosis requires a pathologist’s evaluation of tissue architecture, surgeons often rely on a frozen-section analysis performed during the operation. This rapid read helps guide decisions about how extensive the surgery needs to be. Frozen section is reasonably good at identifying serous borderline tumors, with a sensitivity around 87 percent for the serous subtype in one study.⁶ The trouble arises when the frozen section suggests “at least borderline” with suspicious features: a meta-analysis found that about 41 percent of those ambiguous cases turned out to be invasive cancer on final pathology, compared with roughly 10 percent of cases given a straightforward borderline frozen-section diagnosis.⁷ This leaves surgeons in a genuine bind: operate more aggressively and risk removing tissue unnecessarily, or stay conservative and potentially need a second surgery if the final pathology is worse than expected.

The Molecular Story Behind Serous Borderline Tumors

Serous borderline tumors and high-grade serous ovarian cancers develop through fundamentally different molecular pathways. Borderline tumors are driven by mutations in the KRAS and BRAF genes, both part of the MAPK signaling cascade that tells cells when to grow. These mutations show up early, even in the benign-looking cysts that sit adjacent to the borderline tumor, and are absent in ordinary serous cysts that have no borderline component.⁸ In one small series, seven of eight serous borderline tumors carried either a BRAF or a KRAS mutation, never both at once.⁹ High-grade serous carcinomas, by contrast, are dominated by TP53 mutations and rarely carry KRAS or BRAF changes. This molecular divide helps explain why serous borderline tumors behave so much less aggressively.

Risk Factors

The risk-factor profile for serous borderline tumors overlaps with ovarian cancer in some ways and diverges in others. A Swedish case-control study found that having given birth was protective, cutting the odds of a serous borderline tumor by more than half. Breastfeeding also reduced risk. Surprisingly, oral contraceptive use did not appear to lower risk for the serous subtype, which contrasts with its well-known protective effect against invasive ovarian cancer. Unopposed estrogen replacement therapy roughly doubled the odds, while estrogen paired with a progestin did not carry the same increase. A high body mass index stood out as a strong risk factor: women in the highest BMI category had more than six times the odds of developing a serous borderline tumor compared with leaner women.¹⁰

Surgical Treatment

Surgery is the cornerstone of treatment. The standard approach for women who have completed childbearing involves removal of both ovaries and fallopian tubes, omentectomy (or at minimum an omental biopsy), peritoneal biopsies from multiple sites, and peritoneal cytology. Hysterectomy and lymph node removal are not considered necessary parts of staging for borderline tumors.¹¹ This staging procedure matters because it reveals whether peritoneal implants are present, which changes the prognosis and may affect follow-up planning.

For younger women who want to preserve fertility, conservative surgery is a well-established option. This can mean removing just one ovary and tube, or in select cases performing a cystectomy that preserves the affected ovary itself. The tradeoff is a higher recurrence rate compared with radical surgery, but the recurrences are usually borderline again and are treatable with further surgery rather than chemotherapy.

Fertility After Conservative Surgery

Pregnancy outcomes after fertility-sparing surgery are encouraging. A pooled estimate across published series puts the spontaneous pregnancy rate at around 54 percent, though individual studies report rates ranging from about a third to nearly 90 percent depending on the population and surgical approach.¹² A single-center study found an overall pregnancy rate of about 57 percent among borderline tumor patients who attempted conception, with a live birth rate approaching 89 percent among those who did conceive. Women who married after their treatment had higher conception rates than those who were already married and had previous children, likely reflecting differences in age and active intent to conceive.¹³ Patients with more advanced-stage disease at diagnosis have lower spontaneous pregnancy rates, around 34 percent, so the conversation about fertility preservation should factor in tumor stage.

Why the Micropapillary Pattern Matters

Not all serous borderline tumors carry the same risk. A subset shows a micropapillary growth pattern, in which the papillae are thinner and more elongated, sometimes described as a “Medusa head” appearance. This variant accounts for a minority of cases, roughly 12 percent in a recent meta-analysis of over 1,700 serous borderline tumors. The micropapillary pattern was associated with about seven times the odds of harboring invasive peritoneal implants compared with the typical borderline pattern.¹⁴ Many pathologists now regard the micropapillary serous borderline tumor as essentially an intraepithelial low-grade serous carcinoma. Without invasive implants, these tumors behave similarly to typical borderline tumors, but when invasive implants are present, they tend to act like low-grade carcinomas.¹⁵ This is why thorough surgical staging is so important: the presence or absence of invasive implants determines the clinical trajectory far more than the ovarian tumor alone.

Peritoneal Implants and Their Impact

About a quarter of serous borderline tumors present with peritoneal implants at diagnosis, meaning tumor tissue has settled onto surfaces outside the ovary. The critical question pathologists must answer is whether those implants are noninvasive or invasive. Invasive implants are defined by tissue invading underlying normal structures, a micropapillary architecture within the implant, or solid nests of tumor cells surrounded by clefts.¹⁶ The distinction has a direct effect on survival. Classic work in this area showed that invasion in the implants, severe atypia, and mitotic activity within implants all correlated with worse outcomes.¹⁷

Noninvasive implants, while they can still cause problems, generally do not change the excellent long-term prognosis that most borderline tumors carry. In the meta-analysis of micropapillary tumors discussed above, only about 3.5 percent of serous borderline tumors overall had invasive implants.¹⁴ Those patients are the ones whose disease behaves more like a low-grade carcinoma and who require closer surveillance and sometimes chemotherapy.

Microinvasion and What It Means

Some serous borderline tumors contain tiny foci where tumor cells dip into the stroma. The latest WHO classification allows these microinvasive areas to be up to 5 millimeters across before the tumor would need reclassification.¹⁸ A natural worry is that microinvasion signals the tumor is on its way to becoming a carcinoma. In practice, the evidence is reassuring. One study found that borderline tumors with microinvasion recurred earlier than those without, but the overall rate of recurrence and long-term survival did not differ significantly between the two groups. Fertility-sparing surgery remained feasible for patients with microinvasion, though the authors recommended closer follow-up.¹⁹

The reason microinvasion seems relatively benign may lie in what those invading cells actually are. A morphological and immunohistochemical analysis of 37 cases proposed that the cells in microinvasive foci are not actively proliferating invaders but rather senescent, terminally differentiated cells, some of which are undergoing programmed cell death. They lose expression of estrogen receptor, progesterone receptor, and WT-1, and show a lower proliferation index than the surrounding borderline epithelium.²⁰ If this interpretation holds, microinvasion in a serous borderline tumor is less a warning of imminent carcinoma and more a biological dead end.

Recurrence

Most patients with serous borderline tumors will never experience a recurrence, but the risk is not zero and it stretches over many years. In a Vietnamese cohort of 433 borderline tumor patients, cumulative recurrence rates were about 1 percent at one year, 3 percent at two years, and 5 percent at four years, with a median time to recurrence of 18 months. The factors most strongly linked to recurrence were higher stage at diagnosis, preoperative capsule rupture of the tumor, and cystectomy rather than oophorectomy.²¹ A separate study specifically focusing on serous borderline tumors found that tumor capsule disruption and the micropapillary pattern raised recurrence risk among patients who had fertility-sparing surgery, while noninvasive peritoneal implants raised recurrence risk among those who had radical surgery.²²

Recurrence can appear decades after the original surgery, which is why long-term follow-up is recommended. Routine pelvic ultrasound is the surveillance tool of choice, with particular attention to the remaining ovary in women who had conservative surgery.²³ When a recurrence does happen, it is usually another borderline tumor rather than invasive cancer, and it can typically be managed with reoperation.

The Role of Chemotherapy

One of the most important things to know about serous borderline tumors is that chemotherapy has essentially no role for the vast majority of patients. These tumors proliferate slowly and do not respond well to the cytotoxic drugs used in ovarian cancer. They also do not respond to hormonal therapies despite being estrogen-receptor positive in roughly 90 percent of cases. The single scenario where chemotherapy has shown a benefit is in serous borderline tumors with invasive peritoneal implants, where the treatment regimen mirrors that of invasive carcinoma, typically a platinum-based drug combined with a taxane.²⁴ Radiation therapy has likewise not been shown to improve outcomes.

Transformation to Aggressive Cancer

A small but clinically significant number of serous borderline tumors progress to low-grade serous carcinoma, and in exceedingly rare instances, to high-grade serous carcinoma. The molecular relationship between these stages is the subject of ongoing research. Low-grade serous carcinomas share the KRAS and BRAF mutations seen in borderline tumors, suggesting a stepwise progression. High-grade serous carcinomas, however, are driven by TP53 mutations, so the leap from borderline to high-grade is not straightforward. In a report of three such cases, BRAF and KRAS testing in the high-grade components came back negative, and TP53 mutations were also absent, raising the possibility that these transformations follow a different molecular route than typical high-grade cancers.²⁵

A case report of one such transformation found that the recurrent, aggressive tumor shared the same MAPK-pathway mutations as the original borderline tumor but had acquired additional mutations, including a change in the SMARCA4 gene. SMARCA4 alterations are associated with dedifferentiation and aggressive behavior in various cancers.²⁶ These cases are rare enough that they remain the subject of case reports rather than large trials, but they underscore why even patients with seemingly straightforward borderline tumors benefit from lifelong surveillance.

Differential Diagnosis Pitfalls

Pathologists face several diagnostic traps with serous borderline tumors. When tumor is found on the peritoneum, the differential includes high-grade primary peritoneal papillary serous carcinoma, a primary ovarian borderline tumor with implants, and rarer entities like well-differentiated papillary mesothelioma or reactive mesothelial proliferations. Immunohistochemical staining helps sort these out: serous borderline tumors and their peritoneal implants are typically positive for epithelial markers such as Pan-CK and Ber-EP4 while negative for mesothelial markers like calretinin and D2-40.²⁷ Getting the diagnosis right has direct treatment implications, because high-grade primary peritoneal carcinoma is treated much more aggressively than a borderline tumor with noninvasive implants.

The distinction between a serous borderline tumor and a low-grade serous carcinoma can also be challenging, particularly on frozen section. As noted earlier, the line between the two rests on whether destructive stromal invasion is present. Sampling matters: large tumors need more tissue sections to ensure that an area of frank invasion is not missed, and pathologists occasionally upgrade a borderline diagnosis to carcinoma once permanent sections are reviewed.

Living With a Borderline Diagnosis

For patients, the emotional weight of a borderline ovarian tumor diagnosis can be disproportionate to the medical risk. The cancer label looms large even though the prognosis is excellent for the great majority. Recurrence rates are low, death from the disease is very uncommon at early stages, and fertility can often be preserved. But the open-ended follow-up schedule, the knowledge that late recurrences are possible, and the small but real chance of transformation to carcinoma can produce anxiety that outlasts any physical symptom. Clinicians increasingly recognize that addressing this psychological burden is an important part of care, particularly for younger patients who may spend decades under surveillance. Ultrasound exams every six to twelve months are the standard recommendation, and while the intervals can sometimes be lengthened for patients with many years of stable follow-up, there is no consensus on when it is safe to stop altogether.²³